BAX Quote, Financials, Valuation and Earnings

Alphatec Holdings has a net margin of -18.6% compared to Baxter International's net margin of -18.85%. Baxter International's return on equity of -8.24% beat Alphatec Holdings's return on equity of -691.37%.

Baxter International has a consensus price target of $39.87, signalling upside risk potential of 27.16%. On the other hand Alphatec Holdings has an analysts' consensus of $18.04 which suggests that it could grow by 76.71%. Given that Alphatec Holdings has higher upside potential than Baxter International, analysts believe Alphatec Holdings is more attractive than Baxter International.

Baxter International has a beta of 0.645, which suggesting that the stock is 35.462% less volatile than S&P 500. In comparison Alphatec Holdings has a beta of 1.205, suggesting its more volatile than the S&P 500 by 20.514%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 2.94%. Alphatec Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International pays -90.91% of its earnings as a dividend. Alphatec Holdings pays out -- of its earnings as a dividend.

Baxter International quarterly revenues are $2.8B, which are larger than Alphatec Holdings quarterly revenues of $176.8M. Baxter International's net income of -$512M is lower than Alphatec Holdings's net income of -$33.3M. Notably, Baxter International's price-to-earnings ratio is 167.20x while Alphatec Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 1.25x versus 2.39x for Alphatec Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Becton Dickinson & has a net margin of -18.6% compared to Baxter International's net margin of 5.86%. Baxter International's return on equity of -8.24% beat Becton Dickinson &'s return on equity of 6.75%.

Baxter International has a consensus price target of $39.87, signalling upside risk potential of 27.16%. On the other hand Becton Dickinson & has an analysts' consensus of $276.57 which suggests that it could grow by 24.81%. Given that Baxter International has higher upside potential than Becton Dickinson &, analysts believe Baxter International is more attractive than Becton Dickinson &.

Baxter International has a beta of 0.645, which suggesting that the stock is 35.462% less volatile than S&P 500. In comparison Becton Dickinson & has a beta of 0.349, suggesting its less volatile than the S&P 500 by 65.131%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 2.94%. Becton Dickinson & offers a yield of 1.8% to investors and pays a quarterly dividend of $1.04 per share. Baxter International pays -90.91% of its earnings as a dividend. Becton Dickinson & pays out 64.52% of its earnings as a dividend. Becton Dickinson &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Baxter International quarterly revenues are $2.8B, which are smaller than Becton Dickinson & quarterly revenues of $5.2B. Baxter International's net income of -$512M is lower than Becton Dickinson &'s net income of $303M. Notably, Baxter International's price-to-earnings ratio is 167.20x while Becton Dickinson &'s PE ratio is 36.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 1.25x versus 3.12x for Becton Dickinson &. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of -18.6% compared to Baxter International's net margin of 12.41%. Baxter International's return on equity of -8.24% beat Boston Scientific's return on equity of 8.96%.

Baxter International has a consensus price target of $39.87, signalling upside risk potential of 27.16%. On the other hand Boston Scientific has an analysts' consensus of $115.46 which suggests that it could grow by 17.22%. Given that Baxter International has higher upside potential than Boston Scientific, analysts believe Baxter International is more attractive than Boston Scientific.

Baxter International has a beta of 0.645, which suggesting that the stock is 35.462% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 2.94%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International pays -90.91% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Baxter International quarterly revenues are $2.8B, which are smaller than Boston Scientific quarterly revenues of $4.6B. Baxter International's net income of -$512M is lower than Boston Scientific's net income of $566M. Notably, Baxter International's price-to-earnings ratio is 167.20x while Boston Scientific's PE ratio is 78.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 1.25x versus 8.74x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services has a net margin of -18.6% compared to Baxter International's net margin of 17.38%. Baxter International's return on equity of -8.24% beat West Pharmaceutical Services's return on equity of 18.15%.

Baxter International has a consensus price target of $39.87, signalling upside risk potential of 27.16%. On the other hand West Pharmaceutical Services has an analysts' consensus of $285.01 which suggests that it could grow by 29.57%. Given that West Pharmaceutical Services has higher upside potential than Baxter International, analysts believe West Pharmaceutical Services is more attractive than Baxter International.

Baxter International has a beta of 0.645, which suggesting that the stock is 35.462% less volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.221, suggesting its more volatile than the S&P 500 by 22.112%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 2.94%. West Pharmaceutical Services offers a yield of 0.37% to investors and pays a quarterly dividend of $0.21 per share. Baxter International pays -90.91% of its earnings as a dividend. West Pharmaceutical Services pays out 12% of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Baxter International quarterly revenues are $2.8B, which are larger than West Pharmaceutical Services quarterly revenues of $748.8M. Baxter International's net income of -$512M is lower than West Pharmaceutical Services's net income of $130.1M. Notably, Baxter International's price-to-earnings ratio is 167.20x while West Pharmaceutical Services's PE ratio is 32.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 1.25x versus 5.60x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.